FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Published at www.nejm.org May 7, 2008 (10.1056/NEJMe0802701)

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Maris, J. M. PubMed Citation

Neuroblastoma has a notorious reputation among solid tumors of childhood because of its frequently massive and widespread tumor burden. Yet stage for stage, this embryonal neoplasm of the sympathetic nervous system has become the most curable of the common pediatric solid tumors.¹ More than 90% of patients with localized neuroblastomas, including those with spread to the regional lymph nodes, will survive, often with little or no cytotoxic therapy. Rates of cure of metastatic neuroblastoma exceed 90% among infants (who are usually treated with low-dose chemotherapy) and are approximately 25% among toddlers; in contrast, osteomedullary metastases associated with other pediatric solid . . . [Full Text of this Article]

Source Information

From the Department of Pediatrics, Memorial Sloan-Kettering Cancer Center, New York.

This article (10.1056/NEJMe0802701) was published at www.nejm.org on May 7, 2008. It will appear in the June 12 issue of the Journal.

This article has been cited by other articles:

• (2008). The Genetics of Neuroblastoma. JWatch Neurology 2008: 2-2 [Full Text]